LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
LAVA Therapeutics N.V. - Ordinary Shares (LVTX)
Company Research
Source: Yahoo! Finance
of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. Presentation Details Format: Fireside Chat Date: Tuesday, June 25, 2024 Time: 9:30 AM ET A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavatherapeutics.com/news-events/events . The replay will be archived for 90 days following the presentation date. About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody ® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering V?9Vd2 (Vgamma9
Show less
Read more
Impact Snapshot
Event Time:
LVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LVTX alerts
High impacting LAVA Therapeutics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
LVTX
News
- LAVA Therapeutics (NASDAQ: LVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceGlobeNewswire
- LAVA Announces Annual Meeting of ShareholdersGlobeNewswire
- LAVA Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswire
- LAVA Provides Business Updates and Reports First Quarter 2024 Financial ResultsGlobeNewswire
LVTX
Earnings
- 11/16/23 - Beat
LVTX
Analyst Actions
- 6/28/24 - HC Wainwright
LVTX
Sec Filings
- 6/20/24 - Form 6-K
- 6/6/24 - Form 6-K
- 5/21/24 - Form 6-K
- LVTX's page on the SEC website